bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test
December 09, 2015
Data from the study demonstrate that BCI is a prognostic biomarker for late recurrence among ER-positive breast cancer patients. The data also confirm that HOXB13, part of the Breast Cancer Index, predicted patient benefit from letrozole among ER-positive breast cancer patients.
"For breast cancer patients and the medical professionals who treat them, this is a significant finding," said Dennis Sgroi, MD, Massachusetts General Hospital. "It is our understanding that this is the first time a biomarker has been validated exclusively in the 'late recurrence' setting. It will be a valuable tool to help identify those patients whose disease will most likely recur, as well as those who will benefit from extended therapy."
"In combination with data from the Stockholm cohort presented at last year's SABCS, the data presented today reinforce BCI's unique prognostic value and application for long-term risk prognosis in the breast cancer setting," said Mark Erlander, PhD, chief scientific officer of bioTheranostics.